Sensus Healthcare's SRT Treatment Shows Promise in Treating Cutaneous Mast Cell Tumors Among Pet Patients

Stock Information for Sensus Healthcare Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Sensus Healthcare Inc.

Sensus Healthcare Issues Reminder That its First Quarter 2024 Financial Results and Business Update Conference Call Will be Held on Thursday, May 9, 2024
Sensus Healthcare to Host First Quarter 2024 Financial Results and Business Update Conference Call on Thursday, May 9, 2024
Sensus Healthcare to Participate in the 36th Annual Roth Conference
Sensus Healthcare Launches "Fair Deal Agreement" for its SRT-100 Vision(TM) at the American Academy of Dermatology Annual Meeting
Sensus Healthcare Reports Fourth Quarter and Full Year 2023 Financial Results
Sensus Healthcare Issued U.S. Patent for SRT-100 Vision® System (IG-SRT) Capabilities
Sensus Healthcare Collaborates with CureRays to Provide Oversight to Help Customers Assure Patient Safety, Reliability of Outcomes and Conformance with Regulatory Requirements
Sensus Healthcare Announces Retirement of Director Samuel O'Rear

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.